Search research articles
Contact Us
Filters
Showing results (1111-1120 of 1,154) with videos related to
Page
of 116
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2006
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C Wolff, M Elizabeth H Hammond, Jared N Schwartz, et al.
International Journal of Cancer
|
August 23, 2011
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18
A Szarewski, W A J Poppe, S R Skinner, et al.
The Lancet. Oncology
|
November 15, 2011
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Cosette M Wheeler, Xavier Castellsagué, Suzanne M Garland, et al.
Clinical and Vaccine Immunology : CVI
|
February 6, 2015
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial
Dan Apter, Cosette M Wheeler, Jorma Paavonen, et al.
BMC Infectious Diseases
|
May 1, 2015
Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial
Xavier Castellsagué, Jorma Paavonen, Unnop Jaisamrarn, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 16, 2011
Episodic radiations in the fly tree of life
Brian M Wiegmann, Michelle D Trautwein, Isaac S Winkler, et al.
American Journal of Obstetrics & Gynecology MFM
|
December 21, 2020
Performance of a proteomic preterm delivery predictor in a large independent prospective cohort
Glenn R Markenson, George R Saade, Louise C Laurent, et al.
Journal of Medical Economics
|
November 15, 2022
Clinical and economic evaluation of a proteomic biomarker preterm birth risk predictor: cost-effectiveness modeling of prenatal interventions applied to predicted higher-risk pregnancies within a large and diverse cohort
Julja Burchard, Glenn R Markenson, George R Saade, et al.
The Journal of Infectious Diseases
|
March 11, 2014
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA
Xavier Castellsagué, Paulo Naud, Song-Nan Chow, et al.
Iscience
|
January 11, 2024
From <i>Tg</i>O/GABA-AT, GABA, and T-263 Mutant to Conception of <i>Toxoplasma</i>
Joseph Lykins, Matthew J Moschitto, Ying Zhou, et al.
Page
of 116
Search research articles
Search
Showing results (1111-1120 of 1,154) with videos related to
Sort By:
Page
of 116
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2006
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C Wolff, M Elizabeth H Hammond, Jared N Schwartz, et al.
International Journal of Cancer
|
August 23, 2011
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18
A Szarewski, W A J Poppe, S R Skinner, et al.
The Lancet. Oncology
|
November 15, 2011
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Cosette M Wheeler, Xavier Castellsagué, Suzanne M Garland, et al.
Clinical and Vaccine Immunology : CVI
|
February 6, 2015
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial
Dan Apter, Cosette M Wheeler, Jorma Paavonen, et al.
BMC Infectious Diseases
|
May 1, 2015
Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial
Xavier Castellsagué, Jorma Paavonen, Unnop Jaisamrarn, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 16, 2011
Episodic radiations in the fly tree of life
Brian M Wiegmann, Michelle D Trautwein, Isaac S Winkler, et al.
American Journal of Obstetrics & Gynecology MFM
|
December 21, 2020
Performance of a proteomic preterm delivery predictor in a large independent prospective cohort
Glenn R Markenson, George R Saade, Louise C Laurent, et al.
Journal of Medical Economics
|
November 15, 2022
Clinical and economic evaluation of a proteomic biomarker preterm birth risk predictor: cost-effectiveness modeling of prenatal interventions applied to predicted higher-risk pregnancies within a large and diverse cohort
Julja Burchard, Glenn R Markenson, George R Saade, et al.
The Journal of Infectious Diseases
|
March 11, 2014
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA
Xavier Castellsagué, Paulo Naud, Song-Nan Chow, et al.
Iscience
|
January 11, 2024
From <i>Tg</i>O/GABA-AT, GABA, and T-263 Mutant to Conception of <i>Toxoplasma</i>
Joseph Lykins, Matthew J Moschitto, Ying Zhou, et al.
Page
of 116